← Human Trials & Peer-Reviewed Studies
Contraceptive Continuation and Experiences Obtaining Implant and IUD Removal Among Women Randomized to Use Injectable Contraception, Levonorgestrel Implant, and Copper IUD in South Africa and Zambia.
Plain-language guide to PMID 36727169 (2023): randomized controlled trial of Copper (Supplement) in 674 women.
Key Facts
- PMID
- 36727169
- Journal
- Studies in family planning
- Year
- 2023
- Study type
- Randomized Controlled Trial
- Authors
- Cartwright AF et al. (14 authors)
- DOI
- 10.1111/sifp.12222
What This Study Did, in Plain Language
What Was Tested
Researchers studied Copper (Supplement) in this randomized controlled trial publication.
Few longitudinal studies have measured contraceptive continuation past one year in sub-Saharan Africa.
The researchers surveyed 674 women who had been randomized to receive the three-month intramuscular contraceptive injectable (DMPA-IM), levonorgestrel (LNG) implant, or copper intrauterine device (IUD) during the Evidence for Contraceptive Options and HIV Outcomes (ECHO) trial in South Africa and Zambia and were subsequently followed for two additional years to explore method continuation, reasons for discontinuation, and access to implant and IUD removal services.
Who Took Part
The study group was 674 women.
PubMed tags the participants as women only.
How the Study Was Run
In design terms this was a randomized study.
The women were allocated by chance, so the Copper (Supplement) group and the comparison group should start out alike.
What Was Measured
Few longitudinal studies have measured contraceptive continuation past one year in sub-Saharan Africa.
The researchers surveyed 674 women who had been randomized to receive the three-month intramuscular contraceptive injectable (DMPA-IM), levonorgestrel (LNG) implant, or copper intrauterine device (IUD) during the Evidence for Contraceptive Options and HIV Outcomes (ECHO) trial in South Africa and Zambia and were subsequently followed for two additional years to explore method continuation, reasons for discontinuation, and access to implant and IUD removal services.
Topics PubMed links to this paper include Levonorgestrel, Intrauterine Devices, Copper, South Africa, Zambia, Contraception and Contraceptive Agents, Female.
What This Means in Plain Language
The paper is a randomized study of Copper (Supplement) in 674 women.
With several hundred people or more, it is a fairly large study for this kind of research.
The publication is from 2023 (Studies in family planning), a journal based in United States.
More context: the Copper (Supplement) compound page, all human trials.
Our Notes on the Compound
Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.